Association between the ERCCI rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis

Shou-Cheng Ma1,*, Yue Zhao1,*, Tao Zhang1,*, Xiao-Ling Ling1, Da Zhao1

1Department of Oncology, 2Department of Gastroenterology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, Gansu Province, People’s Republic of China
*These authors contributed equally to this work

Purpose: The relationship between the excision repair cross-complementing 1 (ERCCI) rs11615 polymorphism (C/T) and responses to oxaliplatin-based chemotherapy for gastric cancer (GC) and colorectal cancer (CRC) patients is controversial. Therefore, we performed a meta-analysis to assess this relationship.

Method: Relevant studies were retrieved by searching the PubMed database. A systematic review and meta-analysis was performed to evaluate the predictive value of the ERCCI rs11615 polymorphism for the clinical outcomes of GC and CRC patients receiving oxaliplatin-based chemotherapy. Therapeutic response to chemotherapy, progression-free survival (PFS), and overall survival (OS) were analyzed.

Results: A total of 22 studies were included in this meta-analysis, including 1,242 cases of GC and 1,772 cases of CRC. For the ERCCI rs11615 polymorphism, the T allele was associated with a reduced response to chemotherapy in Asians and GC patients (P<0.05). On the other hand, the T allele was associated with a significant increase in the risk for shorter PFS and OS in all patients (PFS: hazard ratio [HR] = 1.22, P<0.001, 95% confidence interval [CI] = 0.93–1.51 and OS: HR = 1.12, P<0.001, 95% CI = 0.85–1.40).

Conclusion: The ERCCI rs11615 polymorphism was closely associated with the clinical outcomes of GC and CRC patients treated with oxaliplatin-based chemotherapy.

Keywords: ERCCI rs11615, polymorphism, oxaliplatin-based chemotherapy, gastric cancer, colorectal cancer, meta-analysis

Introduction

Gastrointestinal cancer, including gastric cancer (GC) and colorectal cancer (CRC), is a major health problem that accounts for a large proportion of all human malignancies;1 approximately 3.25 million people are diagnosed with the disease each year worldwide.2 Despite recent advances in the diagnosis and therapy of this disease, most gastrointestinal cancer patients present with advanced disease with poor prognoses and low survival rates. Chemotherapy for advanced gastrointestinal cancer has some advantages over best supportive care, including improved quality of life; however, survival does not increase dramatically, with the overall survival (OS) ranging from 6.0 to 12.0 months with chemotherapy.3 Combination treatment with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) is now considered the standard treatment for GC and CRC, with a response rate of over 40% for first-line treatment.4 Oxaliplatin is a frequently used agent that is part of many chemotherapy regimens used to treat several gastrointestinal cancers. It is an organoplatinum complex that can produce both
inter- and intra-strand platinum-DNA cross-links that, in turn, lead to the inhibition of DNA replication and transcription. However, oxaliplatin-based therapies have a critical drawback: tumor cell drug resistance. Although resistance to chemotherapy is multifactorial, DNA repair plays a key role in the resistance of tumors to oxaliplatin.

Excision repair cross-complementing 1 (ERCC1) is a gene encoding a protein of the nucleotide excision repair (NER) complex, which is a group of proteins that are able to repair the DNA damage induced by substances forming adducts, such as platinum. In the past years, the role of single-nucleotide polymorphisms (SNPs) in ERCC1 as predictive factors for treatment outcomes in oxaliplatin-based chemotherapy-treated gastrointestinal cancer patients has been extensively investigated; rs11615 is a common SNP in the coding region of the ERCC1 gene, and its polymorphisms might predict patients’ response to oxaliplatin and the survival of patients with gastrointestinal cancer. However, other studies have suggested that there is no association of the ERCC1 rs11615 polymorphism with the clinical outcomes of gastrointestinal cancer patients receiving oxaliplatin-based chemotherapy. Thus, we performed this meta-analysis to evaluate the effects of the ERCC1 rs11615 (C/T) polymorphisms on the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancer patients by assessing therapeutic response, progression-free survival (PFS), and OS.

Materials and methods

Publication search

This meta-analysis adheres to the relevant criteria of the preferred reporting items for systematic reviews and meta-analyses statement. The PubMed database was searched for material published in English; the latest search was updated on December 20, 2014. The searching strategy consisted of combinations of medical subheadings and key words, such as “gastrointestinal cancer” or “gastric cancer” or “colorectal cancer” and “excision repair cross-complementing 1” or “ERCC1” or “ERCC1 rs11615” and “polymorphisms, single-nucleotide polymorphisms” or “polymorphism” and “oxaliplatin.” All references cited in the original studies or review articles concerning the relevant topic were retrieved to broaden the search for relevant publications.

Inclusion and exclusion criteria

In this meta-analysis, publications of studies that met the following criteria were included: 1) inclusion of gastrointestinal cancer patients (GC and CRC); 2) investigation of the relationship between the ERCC1 rs11615 polymorphism and response to chemotherapy or survival; 3) restriction of the regimen to oxaliplatin-based chemotherapy for investigation of the response to chemotherapy; 4) primary outcomes of interest of objective response, PFS, or OS; and 5) available data for quantitative synthesis, namely, genotype distribution data for response or hazard ratios (HRs) and 95% confidence intervals (CIs) for survival. The following exclusion criteria were used: 1) oxaliplatin-based chemotherapy was used as neoadjuvant treatment; 2) abstracts and reviews; 3) studies without available or exact data; 4) written in a non-English language; and 5) repeated or overlapping publications.

Data extraction

Two authors independently extracted the following items from all of the included studies: name of the first author, publication year of the article, country or area, tumor types (GC or CRC), number of patients, chemotherapy regimens, and genotyping method and outcomes. In addition, the response to chemotherapy according to genotype, HRs for OS and PFS, and their 95% CIs were collected for statistical analysis. We resolved any discrepancies through discussion or by consultation with a third person.

Statistical analysis

Pooled odds ratio (OR) and corresponding 95% CIs were calculated to estimate the association strength of the ERCC1 rs11615 polymorphism (mutant gene vs wild-type gene, TT + CT vs CC) with the response to oxaliplatin-based chemotherapy. PFS and OS were evaluated by using pooled Cox proportional HRs and 95% CIs. A chi-square-based Q-test was used to test the assumption of heterogeneity. If the Q-test suggested a lack of heterogeneity among studies and required the use of the fixed-effects model (the Mantel–Haenszel method) to estimate the pooled OR of all studies. Otherwise, the random effects model was used. Statistical analyses were performed using STATA statistical software (Version 10.0, StataCorp LP, College Station, TX, USA). P<0.05 was considered statistically significant, and all P-values were two sided.

Results

Characteristics of studies

In this meta-analysis, 22 studies were identified to evaluate the relationship between the ERCC1 rs11615 polymorphism and the clinical outcomes of oxaliplatin-based chemotherapy in GC and CRC patients. A total of 3,014 patients with gastrointestinal cancer were enrolled in this study, including 1,242 with GC and 1,772 with CRC.
were 12 studies from Asian populations and 10 from Caucasian populations. Oxaliplatin-based chemotherapy was investigated in all studies, and FOLFOX was the most popular regimen. The most common genotyping methods were polymerase chain reaction and restriction fragment length polymorphism analysis. Characteristics of the eligible studies are summarized in Table 1.

### Association between the ERCCI rs11615 polymorphism and therapeutic response
Fourteen studies including 1,879 patients qualified for analysis of the association between the ERCCI rs11615 polymorphism and therapeutic response in GC and CRC patients. In the dominant model, the mutant gene was not associated with the objective response for all patients (TT vs CC: OR = 1.09, P = 0.337, 95% CI = 0.92–1.28) (Figure 1). However, stratified analysis by ethnicity showed a significant difference in the estimates of the effect between Asians and Caucasians, with the T allele being associated with a significantly lower objective response rate in Asians (TT vs CT vs CC: OR = 1.25, P < 0.001, 95% CI = 1.14–1.38). In addition, in a stratified analysis according to tumor site, the mutant gene was associated with the objective response in GC patients (TT vs CT vs CC: OR = 1.18, P = 0.004, 95% CI = 1.05–1.38) (Table 2).

### Table 1 Study characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Area</th>
<th>N</th>
<th>Tumor types</th>
<th>Genotyping method</th>
<th>Chemotherapy regimen</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martinez-Balbirea et al. 10</td>
<td>Spain</td>
<td>95</td>
<td>mCRC</td>
<td>PCR-RFLP</td>
<td>FOLFOX or XELOX</td>
<td>PFS</td>
</tr>
<tr>
<td>Chang et al. 11</td>
<td>Taiwan</td>
<td>168</td>
<td>CRC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>TR, PFS, OS</td>
</tr>
<tr>
<td>Chen et al. 12</td>
<td>Taiwan</td>
<td>166</td>
<td>mCRC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>TR, OS</td>
</tr>
<tr>
<td>Chua et al. 13</td>
<td>Australia</td>
<td>118</td>
<td>mCRC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>PFS, OS</td>
</tr>
<tr>
<td>Goekkurt et al. 14</td>
<td>Germany</td>
<td>134</td>
<td>GC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>TR</td>
</tr>
<tr>
<td>Etienne-Grimaldi et al. 15</td>
<td>France</td>
<td>117</td>
<td>CRC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>TR, PFS, OS</td>
</tr>
<tr>
<td>Huang et al. 16</td>
<td>People's Republic of China</td>
<td>89</td>
<td>GC</td>
<td>PCR-LDR</td>
<td>FOLFOX</td>
<td>PFS, OS</td>
</tr>
<tr>
<td>Huang et al. 17</td>
<td>People's Republic of China</td>
<td>102</td>
<td>GC</td>
<td>PCR-LDR</td>
<td>FOLFOX</td>
<td>PFS, OS</td>
</tr>
<tr>
<td>Keam et al. 18</td>
<td>Korea</td>
<td>73</td>
<td>GC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>TR, PFS, OS</td>
</tr>
<tr>
<td>Kumamoto et al. 19</td>
<td>Japan</td>
<td>63</td>
<td>mCRC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>TR</td>
</tr>
<tr>
<td>Lamas et al. 20</td>
<td>Spain</td>
<td>72</td>
<td>mCRC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>TR</td>
</tr>
<tr>
<td>Li et al. 21</td>
<td>People's Republic of China</td>
<td>335</td>
<td>CRC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>OS</td>
</tr>
<tr>
<td>Liang et al. 22</td>
<td>People's Republic of China</td>
<td>113</td>
<td>CRC</td>
<td>TaqMan-PCR</td>
<td>FOLFOX or XELOX</td>
<td>TR, PFS, OS</td>
</tr>
<tr>
<td>Liu et al. 23</td>
<td>People's Republic of China</td>
<td>116</td>
<td>GC</td>
<td>TaqMan-PCR</td>
<td>FOLFOX</td>
<td>PFS, OS</td>
</tr>
<tr>
<td>Lu et al. 24</td>
<td>People's Republic of China</td>
<td>447</td>
<td>GC</td>
<td>TaqMan-PCR</td>
<td>FOLFOX</td>
<td>TR, OS</td>
</tr>
<tr>
<td>Paré et al. 25</td>
<td>Spain</td>
<td>126</td>
<td>CRC</td>
<td>TaqMan-PCR</td>
<td>FOLFOX</td>
<td>TR, PFS, OS</td>
</tr>
<tr>
<td>Qi et al. 26</td>
<td>People's Republic of China</td>
<td>206</td>
<td>GC</td>
<td>RT-PCR</td>
<td>FOLFOX</td>
<td>TR</td>
</tr>
<tr>
<td>Ruzzo et al. 27</td>
<td>Italy</td>
<td>166</td>
<td>CRC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>PFS</td>
</tr>
<tr>
<td>Seo et al. 28</td>
<td>Korea</td>
<td>75</td>
<td>GC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>TR, PFS, OS</td>
</tr>
<tr>
<td>Spindler et al. 29</td>
<td>Denmark</td>
<td>66</td>
<td>CRC</td>
<td>PCR</td>
<td>XELOX</td>
<td>TR</td>
</tr>
<tr>
<td>Stoehlmacher et al. 210</td>
<td>USA</td>
<td>106</td>
<td>CRC</td>
<td>PCR-RFLP</td>
<td>FOLFOX</td>
<td>PFS, OS</td>
</tr>
<tr>
<td>Viguier et al. 31</td>
<td>France</td>
<td>61</td>
<td>CRC</td>
<td>PCR</td>
<td>FOLFOX</td>
<td>TR</td>
</tr>
</tbody>
</table>

**Abbreviations:** N, number of patients; mCRC, metastatic colorectal cancer; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; FOLFOX, 5-fluorouracil plus oxaliplatin; XELOX, capecitabine plus oxaliplatin; PFS, progression-free survival; CRC, colorectal cancer; TR, therapeutic response; OS, overall survival; GC, gastric cancer; PCR-LDR, polymerase chain reaction-ligation detection reaction; PCR, polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction.
Figure 1: Association of the ERCC1 rs11615 polymorphism with response to oxaliplatin-based chemotherapy.

Note: Weights are from random-effects analysis.

Abbreviations: ERCC1, excision repair cross-complementing 1; HR, hazard ratio; CI, confidence interval.

Table 2 Association between the ERCC1 rs11615 polymorphism and therapeutic response, PFS, and OS

<table>
<thead>
<tr>
<th>Study</th>
<th>OR/HR (95% CI)</th>
<th>Z-value</th>
<th>P-value</th>
<th>Weight %</th>
</tr>
</thead>
</table>
| Chang et al
t | 1.58 (1.13, 2.21) | 4.58    | <0.001  | 9.08     |
| Chen et al         | 1.60 (1.11, 2.30) | 1.73    | 0.083   | 8.50     |
| Goekkurt et al     | 1.13 (0.65, 1.95) | 2.85    | 0.004   | 6.66     |
| Etienne-Grimaldi et al | 1.04 (0.70, 1.56) | 1.45    | 0.889   | 7.80     |
| Keam et al         | 1.07 (0.64, 1.80) | 1.20    | 0.083   | 6.02     |
| Kumamoto et al     | 0.92 (0.63, 1.36) | 1.23    | 0.012   | 5.08     |
| Lamas et al        | 1.25 (0.99, 1.59) | 0.48    | 0.004   | 8.13     |
| Liang et al        | 1.16 (1.02, 1.32) | 1.45    | 0.004   | 11.12    |
| Lu et al           | 0.82 (0.54, 1.38) | 1.45    | 0.004   | 8.83     |
| Paré et al         | 0.92 (0.54, 1.54) | 1.23    | 0.004   | 2.20     |
| Qi et al           | 1.18 (0.74, 1.30) | 1.23    | 0.004   | 6.77     |
| Seo et al          | 1.21 (0.80, 1.62) | 0.02    | 0.001   | 6.34     |
| Spindler et al     | 1.14 (0.74, 1.81) | 0.14    | 0.001   | 74.4     |
| Viguer et al       | 1.09 (0.92, 1.28) | 0.04    | 0.001   | 100.0    |

In subgroup analysis stratified by ethnicity and tumor site, the significant differences were retained, as shown in Table 2.

Discussion

Oxaliplatin-based chemotherapy is the primary therapeutic option for gastrointestinal cancer, especially for advanced or...
Study | HR (95% CI) | Weight %
--- | --- | ---
Martinez-Balibrea et al$^{10}$ | 0.95 (0.53, 1.71) | 8.74
Chang et al$^{11}$ | 2.60 (1.77, 3.82) | 5.12
Chua et al$^{13}$ | 2.62 (1.14, 6.02) | 1.31
Etienne-Grimaldi et al$^{15}$ | 0.77 (0.48, 1.23) | 11.06
Huang et al$^{16}$ | 1.64 (0.95, 2.83) | 5.68
Huang et al$^{17}$ | 1.08 (0.66, 1.79) | 9.00
Keam et al$^{18}$ | 0.80 (0.49, 1.31) | 10.68
Liang et al$^{22}$ | 1.46 (0.94, 2.27) | 7.98
Liu et al$^{23}$ | 2.22 (1.39, 3.54) | 4.82
Parè et al$^{25}$ | 0.56 (0.37, 0.86) | 12.32
Ruzzo et al$^{27}$ | 1.49 (0.96, 2.29) | 7.98
Seo et al$^{28}$ | 1.31 (0.77, 2.23) | 7.37
Stoehlmacher et al$^{30}$ | 1.27 (0.77, 2.11) | 7.94
Overall ($P=0.000$) | 1.22 (0.93, 1.51) | 100.00

Figure 2 Correlation between the ERCC1 rs11615 polymorphism and progression-free survival.

Note: Weights are from random-effects analysis.

Abbreviations: ERCC1, excision repair cross-complementing 1; HR, hazard ratio; CI, confidence interval.

Study | HR (95% CI) | Weight %
--- | --- | ---
Martinez-Balibrea et al$^{10}$ | 2.12 (1.05, 4.28) | 2.46
Chen et al$^{12}$ | 3.15 (1.89, 5.23) | 2.32
Chua et al$^{13}$ | 1.74 (0.70, 4.31) | 2.03
Etienne-Grimaldi et al$^{15}$ | 0.91 (0.52, 1.57) | 10.23
Huang et al$^{16}$ | 1.31 (0.73, 2.36) | 6.70
Huang et al$^{17}$ | 0.93 (0.54, 1.61) | 10.08
Keam et al$^{18}$ | 1.29 (0.70, 2.37) | 6.51
Li et al$^{21}$ | 0.81 (0.52, 1.14) | 13.51
Liang et al$^{22}$ | 1.46 (0.94, 2.27) | 8.35
Liu et al$^{23}$ | 2.26 (1.37, 3.74) | 4.05
Lu et al$^{24}$ | 0.63 (0.42, 0.94) | 14.24
Parè et al$^{25}$ | 0.56 (0.34, 0.93) | 13.74
Seo et al$^{28}$ | 1.82 (0.87, 3.80) | 2.90
Stoehlmacher et al$^{30}$ | 2.06 (1.06, 4.00) | 2.88
Overall ($P=0.002$) | 1.12 (0.85, 1.40) | 100.00

Figure 3 Correlation between the ERCC1 rs11615 polymorphism and overall survival.

Note: Weights are from random-effects analysis.

Abbreviations: ERCC1, excision repair cross-complementing 1; HR, hazard ratio; CI, confidence interval.
relapsed cancer. The mechanism of action of platinum agents is based on the formation of DNA adducts that result in the alteration of the DNA structure and, eventually, the inhibition of DNA replication and transcription.\textsuperscript{32} Hence, the expression of genes involved in the mechanisms of DNA repair has been studied as a possible predictive factor in patients treated with platinum-based chemotherapy.\textsuperscript{33} ERCCI, which has a variety of gene forms, is the lead enzyme in the NER DNA repair pathway.\textsuperscript{34} The DNA repair system plays a vital role in maintaining the stability of cellular functions and genomic integrity through the reversal of the DNA damage induced by various endogenous and/or exogenous factors, including therapeutic agents; therefore, host DNA repair capacity may contribute to cancer patient outcomes.\textsuperscript{35} One possible theory postulates that in the absence of platinum therapy, poor DNA repair may result in more biologically aggressive tumors through their susceptibility to greater genetic aberrations over time, resulting in worse outcomes.\textsuperscript{36}

The different polymorphisms of \textit{ERCC1} may be related to the effect of chemotherapy in cancer patients. \textit{ERCC1} rs11615 (C to T), belonging to the NER pathway, is associated with its diminished expression levels (mRNA and protein), with downstream functional consequences in the repair of cisplatin-induced DNA lesions. Recently, the \textit{ERCC1} rs11615 gene polymorphism was shown to provide better prognostic information for cancer patients treated with platinum-based chemotherapy, including those with non-small cell lung cancer, ovarian cancer, testicular germ cell tumors, and gastrointestinal cancer.\textsuperscript{37–40} Previous studies have revealed that \textit{ERCC1} rs11615 genotypes are associated with the clinical outcome of GC or CRC patients who receive oxaliplatin-based chemotherapy, but the end results of these studies are not consistent, and current evidence is insufficient to confirm a statistically significant correlation. Some references describing association of rs11615 with \textit{ERCC1} diminished expression.\textsuperscript{7,8,25,29,31} This meta-analysis examined the association between the \textit{ERCC1} rs11615 polymorphism and the clinical outcomes of gastric and CRCs that were treated by oxaliplatin-based chemotherapy. Therapeutic response, PFS, and OS were used as the main parameters. We found no statistical evidence for an association between two \textit{ERCC1} rs11615 SNPs and the objective response for all patients. However, stratified analysis indicated the \textit{ERCC1} rs11615 T allele was a biomarker of low therapeutic response in Asian patients and GC patients. At the same time, our meta-analysis provided evidence that the \textit{ERCC1} rs11615 polymorphism was associated with PFS or OS. Notably, there was an apparent ethnic discrepancy in the prognostic value between Asians and Caucasians, and statistical tests also confirmed the existence of ethnic differences in the estimates of the effect of the \textit{ERCC1} allele. This discrepancy could be explained by the fact that the treatment outcome of platinum agents may be influenced by gene–gene interactions in different genetic backgrounds and gene–environment interactions in different lifestyles. As the previous studies gave controversial results, there may be some other reasons, such as the following: 1) different pathological types (GC and CRC) may produce different results; 2) there was different incidences of GC or CRC in different regions of worldwide, for example, higher incidence of GC in East Asia; 3) the positive result of some studies might be attributed to small sample size; 4) the other factors of population included cannot be analyzed in detail, such as age, sex, smoking, and drinking status, which could make the result masked; and 5) some studies are hospital-based design, which would not represent the people who live in a certain region.

Attention should be paid to the limitations of the meta-analysis, although some effort was made to perform a precise and comprehensive analysis. First, there are very few studies comparing Asians and Caucasians, with even fewer involving the black population. Further, with original data lacking for every study, we could only present an extensive subgroup analysis. In addition, the differences in national characteristics in different regions are influencing factors in the study results. Oxaliplatin is used with 5-fluorouracil in the regimen, and not as a single compound, and owing to the limited available publications on the subject, the latent gene–gene associations between NER variants and folate-metabolizing gene variants still cannot be investigated. Finally, some confounding factors such as sex, age, TNM stage, and chemotherapy regimens can never change the results based on the initial data.

To summarize, polymorphisms of \textit{ERCC1} rs11615 are closely associated with the clinical outcomes of GC and CRC patients treated with oxaliplatin-based chemotherapy. Future studies with larger sample sizes using multivariate analyses may provide more persuasive data on this putative association.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


